Lung Cancer - Multimodality Therapy

JANS Article

Surgical Outcomes After Chemotherapy Plus Nivolumab and Chemotherapy Plus Nivolumab and Ipilimumab in Patients With Non-Small Cell Lung Cancer

April 18, 2024 | Mujtaba MubashirGold Contributor

This study reviews 44 patients with stage IB (larger than 4 cm) to IIIA non-small cell lung cancer who were treated on sequential platform arms of the NEOSTAR trial. Twenty-two patients were treated with nivolumab...

JANS Article

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

November 10, 2023 | Aristotle ProtopapasGold Commentor

A manuscript that wil certainly be discussed in lung MDT! The thought of a RCT in these earlier stages may be already in the mind of the sponsors… The authors...

JANS Article

Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer

November 9, 2023 | Javeria Tariq

This paper looked at the immunotherapy agent Durvalumab used in the perioperative period for resectable NSCLC. A total of 802 patients were enrolled in the study, of which 400 received...

JANS Article

The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and Multidisciplinary Management of Patients with Early-Stage Non-Small Cell Lung Cancer

June 15, 2023 | Cameron LindSilver Contributor

A new expert consensus on diagnosis, staging, and therapy for early-stage non-small cell lung cancer patients has been released. The experts recommend CT and PET imaging as a necessary part...

JANS Article

NIH Grant Funds Cancer Prevention Vaccine Research

December 9, 2022 | Cameron LindSilver Contributor

Researchers have been awarded a grant to fund cancer vaccine research, including the development of an mRNA vaccine that would target precancerous lung lesions. Eventually, researchers hope to develop an...

JANS Article

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

May 26, 2022 | Aristotle ProtopapasGold Commentor

No statistical significance ,between the two arms, regarding the OVERALL survival in this RCT funded by the supplier and manufacturer of the immunotherapy in question….

...
JANS Article

Lung Cancer in France

January 27, 2021 | Aristotle ProtopapasGold Commentor

An open-access detailed editorial from the official periodical of the International Association for the Study of Lung Cancer

...
JANS Article

Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer

November 21, 2020 | Aristotle ProtopapasGold Commentor

A scholarly and sober narrative review on , as the authors state, a ‘ hot topic’ that is already being debated in Multidisciplinary Meetings and Lung Cnacer Boards.

...
JANS Article

A Remarkable Drop in Lung Cancer Mortality

January 10, 2020 | Mark FergusonBronze Contributor

Declines in US annual lung cancer mortality rates of 5% for men and 4% for women led improvements in overall cancer mortality rates in the latest update from the American...

JANS Article

Year in Review: Lung Cancer

November 7, 2019 | Mark FergusonBronze Contributor

This brief overview of recently presented improvements in lung cancer therapy highlights the substantial benefits of newer chemotherapy and immunotherapy regimens that are transforming the outlooks of many patients with...

JANS Article

Endobronchial and Surgical Treatment of Pulmonary Carcinoid Tumors: A Systematic Literature Review

August 8, 2019 | Aristotle ProtopapasGold Commentor

A detailed and robust meta-analysis asserting lack of strong evidence supporting either modality.

...
JANS Article

Survival Following Multimodality Treatment Including Surgery for Stage IA–IIIB Small-Cell Lung Cancer

June 13, 2019 | Claire Vernon

To evaluate the benefit of multimodality treatment for patients with limited disease small-cell lung cancer, Weckler and colleagues retrospectively reviewed outcomes for 47 patients treated at their institution between 1999...

JANS Article

A Year at the Forefront of General Thoracic Surgery

April 17, 2019 | Wei-Guo Ma

Dr Burt gives a brief overview of the considerable advances for patients with thoracic malignancies (non–small cell lung cancer in particular).

...
LOAD MORE
ADVERTISE ON CTSNET